Summary
According to APO Research, The global Follicular Lymphoma Drugs market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Follicular Lymphoma Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Follicular Lymphoma Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Follicular Lymphoma Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Follicular Lymphoma Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Follicular Lymphoma Drugs include Roche, Gilead Sciences, TG Therapeutics, Bayer, Secura Bio, Epizyme, Eisai, Acrotech Biopharma and Teva, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Follicular Lymphoma Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Follicular Lymphoma Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Follicular Lymphoma Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Follicular Lymphoma Drugs revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Follicular Lymphoma Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Follicular Lymphoma Drugs revenue, projected growth trends, production technology, application and end-user industry.
Follicular Lymphoma Drugs segment by Company
Roche
Gilead Sciences
TG Therapeutics
Bayer
Secura Bio
Epizyme
Eisai
Acrotech Biopharma
Teva
Eagle Pharmaceuticals
MundiPharma
Follicular Lymphoma Drugs segment by Type
Anti-CD20 mAbs
Chemotherapy Agents
Kinase Inhibitor
Others
Follicular Lymphoma Drugs segment by Administration Route
Injection
Oral
Follicular Lymphoma Drugs segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Follicular Lymphoma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Follicular Lymphoma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Follicular Lymphoma Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Follicular Lymphoma Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Follicular Lymphoma Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Follicular Lymphoma Drugs revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
1 Market Overview
1.1 Product Definition
1.2 Follicular Lymphoma Drugs Market by Type
1.2.1 Global Follicular Lymphoma Drugs Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Anti-CD20 mAbs
1.2.3 Chemotherapy Agents
1.2.4 Kinase Inhibitor
1.2.5 Others
1.3 Follicular Lymphoma Drugs Market by Administration Route
1.3.1 Global Follicular Lymphoma Drugs Market Size by Administration Route, 2019 VS 2023 VS 2030
1.3.2 Injection
1.3.3 Oral
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Follicular Lymphoma Drugs Market Dynamics
2.1 Follicular Lymphoma Drugs Industry Trends
2.2 Follicular Lymphoma Drugs Industry Drivers
2.3 Follicular Lymphoma Drugs Industry Opportunities and Challenges
2.4 Follicular Lymphoma Drugs Industry Restraints
3 Global Growth Perspective
3.1 Global Follicular Lymphoma Drugs Market Perspective (2019-2030)
3.2 Global Follicular Lymphoma Drugs Growth Trends by Region
3.2.1 Global Follicular Lymphoma Drugs Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Follicular Lymphoma Drugs Market Size by Region (2019-2024)
3.2.3 Global Follicular Lymphoma Drugs Market Size by Region (2025-2030)
4 Competitive Landscape by Players
4.1 Global Follicular Lymphoma Drugs Revenue by Players
4.1.1 Global Follicular Lymphoma Drugs Revenue by Players (2019-2024)
4.1.2 Global Follicular Lymphoma Drugs Revenue Market Share by Players (2019-2024)
4.1.3 Global Follicular Lymphoma Drugs Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Follicular Lymphoma Drugs Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Follicular Lymphoma Drugs Key Players Headquarters & Area Served
4.4 Global Follicular Lymphoma Drugs Players, Product Type & Application
4.5 Global Follicular Lymphoma Drugs Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Follicular Lymphoma Drugs Market CR5 and HHI
4.6.2 Global Top 5 and 10 Follicular Lymphoma Drugs Players Market Share by Revenue in 2023
4.6.3 2023 Follicular Lymphoma Drugs Tier 1, Tier 2, and Tier 3
5 Follicular Lymphoma Drugs Market Size by Type
5.1 Global Follicular Lymphoma Drugs Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Follicular Lymphoma Drugs Revenue by Type (2019-2030)
5.3 Global Follicular Lymphoma Drugs Revenue Market Share by Type (2019-2030)
6 Follicular Lymphoma Drugs Market Size by Application
6.1 Global Follicular Lymphoma Drugs Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Follicular Lymphoma Drugs Revenue by Application (2019-2030)
6.3 Global Follicular Lymphoma Drugs Revenue Market Share by Application (2019-2030)
7 Company Profiles
7.1 Roche
7.1.1 Roche Comapny Information
7.1.2 Roche Business Overview
7.1.3 Roche Follicular Lymphoma Drugs Revenue and Gross Margin (2019-2024)
7.1.4 Roche Follicular Lymphoma Drugs Product Portfolio
7.1.5 Roche Recent Developments
7.2 Gilead Sciences
7.2.1 Gilead Sciences Comapny Information
7.2.2 Gilead Sciences Business Overview
7.2.3 Gilead Sciences Follicular Lymphoma Drugs Revenue and Gross Margin (2019-2024)
7.2.4 Gilead Sciences Follicular Lymphoma Drugs Product Portfolio
7.2.5 Gilead Sciences Recent Developments
7.3 TG Therapeutics
7.3.1 TG Therapeutics Comapny Information
7.3.2 TG Therapeutics Business Overview
7.3.3 TG Therapeutics Follicular Lymphoma Drugs Revenue and Gross Margin (2019-2024)
7.3.4 TG Therapeutics Follicular Lymphoma Drugs Product Portfolio
7.3.5 TG Therapeutics Recent Developments
7.4 Bayer
7.4.1 Bayer Comapny Information
7.4.2 Bayer Business Overview
7.4.3 Bayer Follicular Lymphoma Drugs Revenue and Gross Margin (2019-2024)
7.4.4 Bayer Follicular Lymphoma Drugs Product Portfolio
7.4.5 Bayer Recent Developments
7.5 Secura Bio
7.5.1 Secura Bio Comapny Information
7.5.2 Secura Bio Business Overview
7.5.3 Secura Bio Follicular Lymphoma Drugs Revenue and Gross Margin (2019-2024)
7.5.4 Secura Bio Follicular Lymphoma Drugs Product Portfolio
7.5.5 Secura Bio Recent Developments
7.6 Epizyme
7.6.1 Epizyme Comapny Information
7.6.2 Epizyme Business Overview
7.6.3 Epizyme Follicular Lymphoma Drugs Revenue and Gross Margin (2019-2024)
7.6.4 Epizyme Follicular Lymphoma Drugs Product Portfolio
7.6.5 Epizyme Recent Developments
7.7 Eisai
7.7.1 Eisai Comapny Information
7.7.2 Eisai Business Overview
7.7.3 Eisai Follicular Lymphoma Drugs Revenue and Gross Margin (2019-2024)
7.7.4 Eisai Follicular Lymphoma Drugs Product Portfolio
7.7.5 Eisai Recent Developments
7.8 Acrotech Biopharma
7.8.1 Acrotech Biopharma Comapny Information
7.8.2 Acrotech Biopharma Business Overview
7.8.3 Acrotech Biopharma Follicular Lymphoma Drugs Revenue and Gross Margin (2019-2024)
7.8.4 Acrotech Biopharma Follicular Lymphoma Drugs Product Portfolio
7.8.5 Acrotech Biopharma Recent Developments
7.9 Teva
7.9.1 Teva Comapny Information
7.9.2 Teva Business Overview
7.9.3 Teva Follicular Lymphoma Drugs Revenue and Gross Margin (2019-2024)
7.9.4 Teva Follicular Lymphoma Drugs Product Portfolio
7.9.5 Teva Recent Developments
7.10 Eagle Pharmaceuticals
7.10.1 Eagle Pharmaceuticals Comapny Information
7.10.2 Eagle Pharmaceuticals Business Overview
7.10.3 Eagle Pharmaceuticals Follicular Lymphoma Drugs Revenue and Gross Margin (2019-2024)
7.10.4 Eagle Pharmaceuticals Follicular Lymphoma Drugs Product Portfolio
7.10.5 Eagle Pharmaceuticals Recent Developments
7.11 MundiPharma
7.11.1 MundiPharma Comapny Information
7.11.2 MundiPharma Business Overview
7.11.3 MundiPharma Follicular Lymphoma Drugs Revenue and Gross Margin (2019-2024)
7.11.4 MundiPharma Follicular Lymphoma Drugs Product Portfolio
7.11.5 MundiPharma Recent Developments
8 North America
8.1 North America Follicular Lymphoma Drugs Revenue (2019-2030)
8.2 North America Follicular Lymphoma Drugs Revenue by Type (2019-2030)
8.2.1 North America Follicular Lymphoma Drugs Revenue by Type (2019-2024)
8.2.2 North America Follicular Lymphoma Drugs Revenue by Type (2025-2030)
8.3 North America Follicular Lymphoma Drugs Revenue Share by Type (2019-2030)
8.4 North America Follicular Lymphoma Drugs Revenue by Administration Route (2019-2030)
8.4.1 North America Follicular Lymphoma Drugs Revenue by Administration Route (2019-2024)
8.4.2 North America Follicular Lymphoma Drugs Revenue by Administration Route (2025-2030)
8.5 North America Follicular Lymphoma Drugs Revenue Share by Administration Route (2019-2030)
8.6 North America Follicular Lymphoma Drugs Revenue by Country
8.6.1 North America Follicular Lymphoma Drugs Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Follicular Lymphoma Drugs Revenue by Country (2019-2024)
8.6.3 North America Follicular Lymphoma Drugs Revenue by Country (2025-2030)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Follicular Lymphoma Drugs Revenue (2019-2030)
9.2 Europe Follicular Lymphoma Drugs Revenue by Type (2019-2030)
9.2.1 Europe Follicular Lymphoma Drugs Revenue by Type (2019-2024)
9.2.2 Europe Follicular Lymphoma Drugs Revenue by Type (2025-2030)
9.3 Europe Follicular Lymphoma Drugs Revenue Share by Type (2019-2030)
9.4 Europe Follicular Lymphoma Drugs Revenue by Administration Route (2019-2030)
9.4.1 Europe Follicular Lymphoma Drugs Revenue by Administration Route (2019-2024)
9.4.2 Europe Follicular Lymphoma Drugs Revenue by Administration Route (2025-2030)
9.5 Europe Follicular Lymphoma Drugs Revenue Share by Administration Route (2019-2030)
9.6 Europe Follicular Lymphoma Drugs Revenue by Country
9.6.1 Europe Follicular Lymphoma Drugs Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Follicular Lymphoma Drugs Revenue by Country (2019-2024)
9.6.3 Europe Follicular Lymphoma Drugs Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 China
10.1 China Follicular Lymphoma Drugs Revenue (2019-2030)
10.2 China Follicular Lymphoma Drugs Revenue by Type (2019-2030)
10.2.1 China Follicular Lymphoma Drugs Revenue by Type (2019-2024)
10.2.2 China Follicular Lymphoma Drugs Revenue by Type (2025-2030)
10.3 China Follicular Lymphoma Drugs Revenue Share by Type (2019-2030)
10.4 China Follicular Lymphoma Drugs Revenue by Administration Route (2019-2030)
10.4.1 China Follicular Lymphoma Drugs Revenue by Administration Route (2019-2024)
10.4.2 China Follicular Lymphoma Drugs Revenue by Administration Route (2025-2030)
10.5 China Follicular Lymphoma Drugs Revenue Share by Administration Route (2019-2030)
11 Asia (Excluding China)
11.1 Asia Follicular Lymphoma Drugs Revenue (2019-2030)
11.2 Asia Follicular Lymphoma Drugs Revenue by Type (2019-2030)
11.2.1 Asia Follicular Lymphoma Drugs Revenue by Type (2019-2024)
11.2.2 Asia Follicular Lymphoma Drugs Revenue by Type (2025-2030)
11.3 Asia Follicular Lymphoma Drugs Revenue Share by Type (2019-2030)
11.4 Asia Follicular Lymphoma Drugs Revenue by Administration Route (2019-2030)
11.4.1 Asia Follicular Lymphoma Drugs Revenue by Administration Route (2019-2024)
11.4.2 Asia Follicular Lymphoma Drugs Revenue by Administration Route (2025-2030)
11.5 Asia Follicular Lymphoma Drugs Revenue Share by Administration Route (2019-2030)
11.6 Asia Follicular Lymphoma Drugs Revenue by Country
11.6.1 Asia Follicular Lymphoma Drugs Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Follicular Lymphoma Drugs Revenue by Country (2019-2024)
11.6.3 Asia Follicular Lymphoma Drugs Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 Middle East, Africa, Latin America
12.1 MEALA Follicular Lymphoma Drugs Revenue (2019-2030)
12.2 MEALA Follicular Lymphoma Drugs Revenue by Type (2019-2030)
12.2.1 MEALA Follicular Lymphoma Drugs Revenue by Type (2019-2024)
12.2.2 MEALA Follicular Lymphoma Drugs Revenue by Type (2025-2030)
12.3 MEALA Follicular Lymphoma Drugs Revenue Share by Type (2019-2030)
12.4 MEALA Follicular Lymphoma Drugs Revenue by Administration Route (2019-2030)
12.4.1 MEALA Follicular Lymphoma Drugs Revenue by Administration Route (2019-2024)
12.4.2 MEALA Follicular Lymphoma Drugs Revenue by Administration Route (2025-2030)
12.5 MEALA Follicular Lymphoma Drugs Revenue Share by Administration Route (2019-2030)
12.6 MEALA Follicular Lymphoma Drugs Revenue by Country
12.6.1 MEALA Follicular Lymphoma Drugs Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Follicular Lymphoma Drugs Revenue by Country (2019-2024)
12.6.3 MEALA Follicular Lymphoma Drugs Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
List of Tables
Table 1. Global Follicular Lymphoma Drugs Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Anti-CD20 mAbs Major Manufacturers
Table 2. Chemotherapy Agents Major Manufacturers
Table 3. Kinase Inhibitor Major Manufacturers
Table 4. Others Major Manufacturers
Table 5. Global Follicular Lymphoma Drugs Market Size Growth Rate by Administration Route (US$ Million), 2019 VS 2023 VS 2030
Table 6. Injection Major Manufacturers
Table 7. Oral Major Manufacturers
Table 8. Follicular Lymphoma Drugs Industry Trends
Table 9. Follicular Lymphoma Drugs Industry Drivers
Table 10. Follicular Lymphoma Drugs Industry Opportunities and Challenges
Table 11. Follicular Lymphoma Drugs Industry Restraints
Table 12. Global Follicular Lymphoma Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 13. Global Follicular Lymphoma Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 14. Global Follicular Lymphoma Drugs Market Share by Region (2019-2024)
Table 15. Global Follicular Lymphoma Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 16. Global Follicular Lymphoma Drugs Market Share by Region (2025-2030)
Table 17. Global Follicular Lymphoma Drugs Revenue by Players (US$ Million) & (2019-2024)
Table 18. Global Follicular Lymphoma Drugs Revenue Market Share by Players (2019-2024)
Table 19. Global Follicular Lymphoma Drugs Key Players Ranking, 2022 VS 2023 VS 2024
Table 20. Global Follicular Lymphoma Drugs Key Players Headquarters & Area Served
Table 21. Global Follicular Lymphoma Drugs Players, Product Type & Application
Table 22. Global Follicular Lymphoma Drugs Players Commercialization Time
Table 23. Global Players Market Concentration Ratio (CR5 and HHI)
Table 24. Global Follicular Lymphoma Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 25. Global Follicular Lymphoma Drugs Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 26. Global Follicular Lymphoma Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 27. Global Follicular Lymphoma Drugs Revenue by Type (2025-2030) & (US$ Million)
Table 28. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 29. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 30. Global Follicular Lymphoma Drugs Revenue by Administration Route 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Global Follicular Lymphoma Drugs Revenue by Administration Route (2019-2024) & (US$ Million)
Table 32. Global Follicular Lymphoma Drugs Revenue by Administration Route (2025-2030) & (US$ Million)
Table 33. Global Follicular Lymphoma Drugs Revenue Market Share by Administration Route (2019-2024) & (US$ Million)
Table 34. Global Follicular Lymphoma Drugs Revenue Market Share by Administration Route (2025-2030) & (US$ Million)
Table 35. Roche Company Information
Table 36. Roche Business Overview
Table 37. Roche Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 38. Roche Follicular Lymphoma Drugs Product Portfolio
Table 39. Roche Recent Development
Table 40. Gilead Sciences Company Information
Table 41. Gilead Sciences Business Overview
Table 42. Gilead Sciences Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 43. Gilead Sciences Follicular Lymphoma Drugs Product Portfolio
Table 44. Gilead Sciences Recent Development
Table 45. TG Therapeutics Company Information
Table 46. TG Therapeutics Business Overview
Table 47. TG Therapeutics Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 48. TG Therapeutics Follicular Lymphoma Drugs Product Portfolio
Table 49. TG Therapeutics Recent Development
Table 50. Bayer Company Information
Table 51. Bayer Business Overview
Table 52. Bayer Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 53. Bayer Follicular Lymphoma Drugs Product Portfolio
Table 54. Bayer Recent Development
Table 55. Secura Bio Company Information
Table 56. Secura Bio Business Overview
Table 57. Secura Bio Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 58. Secura Bio Follicular Lymphoma Drugs Product Portfolio
Table 59. Secura Bio Recent Development
Table 60. Epizyme Company Information
Table 61. Epizyme Business Overview
Table 62. Epizyme Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 63. Epizyme Follicular Lymphoma Drugs Product Portfolio
Table 64. Epizyme Recent Development
Table 65. Eisai Company Information
Table 66. Eisai Business Overview
Table 67. Eisai Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 68. Eisai Follicular Lymphoma Drugs Product Portfolio
Table 69. Eisai Recent Development
Table 70. Acrotech Biopharma Company Information
Table 71. Acrotech Biopharma Business Overview
Table 72. Acrotech Biopharma Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 73. Acrotech Biopharma Follicular Lymphoma Drugs Product Portfolio
Table 74. Acrotech Biopharma Recent Development
Table 75. Teva Company Information
Table 76. Teva Business Overview
Table 77. Teva Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 78. Teva Follicular Lymphoma Drugs Product Portfolio
Table 79. Teva Recent Development
Table 80. Eagle Pharmaceuticals Company Information
Table 81. Eagle Pharmaceuticals Business Overview
Table 82. Eagle Pharmaceuticals Follicular Lymphoma Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 83. Eagle Pharmaceuticals Follicular Lymphoma Drugs Product Portfolio
Table 84. Eagle Pharmaceuticals Recent Development
Table 85. MundiPharma Company Information
Table 86. MundiPharma Business Overview
Table 87. MundiPharma Follicular Lymphoma Drugs Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)
Table 88. MundiPharma Follicular Lymphoma Drugs Product Portfolio
Table 89. MundiPharma Recent Development
Table 90. North America Follicular Lymphoma Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 91. North America Follicular Lymphoma Drugs Revenue by Administration Route (2019-2024) & (US$ Million)
Table 92. North America Follicular Lymphoma Drugs Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 93. North America Follicular Lymphoma Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 94. North America Follicular Lymphoma Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 95. Europe Follicular Lymphoma Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 96. Europe Follicular Lymphoma Drugs Revenue by Administration Route (2019-2024) & (US$ Million)
Table 97. Europe Follicular Lymphoma Drugs Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 98. Europe Follicular Lymphoma Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 99. Europe Follicular Lymphoma Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 100. China Follicular Lymphoma Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 101. China Follicular Lymphoma Drugs Revenue by Administration Route (2019-2024) & (US$ Million)
Table 102. Asia Follicular Lymphoma Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 103. Asia Follicular Lymphoma Drugs Revenue by Administration Route (2019-2024) & (US$ Million)
Table 104. Asia Follicular Lymphoma Drugs Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 105. Asia Follicular Lymphoma Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 106. Asia Follicular Lymphoma Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 107. MEALA Follicular Lymphoma Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 108. MEALA Follicular Lymphoma Drugs Revenue by Administration Route (2019-2024) & (US$ Million)
Table 109. MEALA Follicular Lymphoma Drugs Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 110. MEALA Follicular Lymphoma Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 111. MEALA Follicular Lymphoma Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 112. Research Programs/Design for This Report
Table 113. Authors List of This Report
Table 114. Secondary Sources
Table 115. Primary Sources
List of Figures
Figure 1. Follicular Lymphoma Drugs Product Picture
Figure 2. Global Follicular Lymphoma Drugs Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Follicular Lymphoma Drugs Market Size Share 2019 VS 2023 VS 2030
Figure 4. Anti-CD20 mAbs Picture
Figure 5. Chemotherapy Agents Picture
Figure 6. Kinase Inhibitor Picture
Figure 7. Others Picture
Figure 8. Global Follicular Lymphoma Drugs Market Size Growth Rate by Administration Route (US$ Million), 2019 VS 2023 VS 2030
Figure 9. Global Follicular Lymphoma Drugs Market Size Share 2019 VS 2023 VS 2030
Figure 10. Injection Picture
Figure 11. Oral Picture
Figure 12. Global Follicular Lymphoma Drugs Market Size (US$ Million) & (2019-2030)
Figure 13. Global Follicular Lymphoma Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Follicular Lymphoma Drugs Market Share by Region: 2019 VS 2023 VS 2030
Figure 15. Global Follicular Lymphoma Drugs Players Revenue Share Top 10 and Top 5 in 2023
Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 17. Global Follicular Lymphoma Drugs Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global Follicular Lymphoma Drugs Revenue Market Share 2019 VS 2023 VS 2030
Figure 19. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2019-2030)
Figure 20. Global Follicular Lymphoma Drugs Revenue by Administration Route (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global Follicular Lymphoma Drugs Revenue Market Share by Administration Route (2019 VS 2023 VS 2030)
Figure 22. Global Follicular Lymphoma Drugs Revenue Market Share by Administration Route (2019-2030)
Figure 23. North America Follicular Lymphoma Drugs Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 24. North America Follicular Lymphoma Drugs Revenue by Type (2025-2030) & (US$ Million)
Figure 25. North America Follicular Lymphoma Drugs Revenue Share by Type (2019-2030)
Figure 26. North America Follicular Lymphoma Drugs Revenue by Application (2025-2030) & (US$ Million)
Figure 27. North America Follicular Lymphoma Drugs Revenue Share by Application (2019-2030)
Figure 28. North America Follicular Lymphoma Drugs Revenue Share by Country (2019-2030)
Figure 29. United States Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 30. Canada Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 31. Europe Follicular Lymphoma Drugs Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 32. Europe Follicular Lymphoma Drugs Revenue by Type (2025-2030) & (US$ Million)
Figure 33. Europe Follicular Lymphoma Drugs Revenue Share by Type (2019-2030)
Figure 34. Europe Follicular Lymphoma Drugs Revenue by Application (2025-2030) & (US$ Million)
Figure 35. Europe Follicular Lymphoma Drugs Revenue Share by Application (2019-2030)
Figure 36. Europe Follicular Lymphoma Drugs Revenue Share by Country (2019-2030)
Figure 37. Germany Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 38. France Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 39. U.K. Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 40. Italy Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 41. Russia Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. Nordic Countries Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. China Follicular Lymphoma Drugs Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 44. China Follicular Lymphoma Drugs Revenue by Type (2025-2030) & (US$ Million)
Figure 45. China Follicular Lymphoma Drugs Revenue Share by Type (2019-2030)
Figure 46. China Follicular Lymphoma Drugs Revenue by Application (2025-2030) & (US$ Million)
Figure 47. China Follicular Lymphoma Drugs Revenue Share by Application (2019-2030)
Figure 48. Asia Follicular Lymphoma Drugs Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 49. Asia Follicular Lymphoma Drugs Revenue by Type (2025-2030) & (US$ Million)
Figure 50. Asia Follicular Lymphoma Drugs Revenue Share by Type (2019-2030)
Figure 51. Asia Follicular Lymphoma Drugs Revenue by Application (2025-2030) & (US$ Million)
Figure 52. Asia Follicular Lymphoma Drugs Revenue Share by Application (2019-2030)
Figure 53. Asia Follicular Lymphoma Drugs Revenue Share by Country (2019-2030)
Figure 54. Japan Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 55. South Korea Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 56. India Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 57. Australia Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 58. China Taiwan Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. Southeast Asia Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 60. MEALA Follicular Lymphoma Drugs Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 61. MEALA Follicular Lymphoma Drugs Revenue by Type (2025-2030) & (US$ Million)
Figure 62. MEALA Follicular Lymphoma Drugs Revenue Share by Type (2019-2030)
Figure 63. MEALA Follicular Lymphoma Drugs Revenue by Application (2025-2030) & (US$ Million)
Figure 64. MEALA Follicular Lymphoma Drugs Revenue Share by Application (2019-2030)
Figure 65. MEALA Follicular Lymphoma Drugs Revenue Share by Country (2019-2030)
Figure 66. Mexico Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 67. South Korea Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 68. Brazil Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 69. Israel Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 70. Argentina Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 71. Colombia Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 72. Turkey Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 73. Saudi Arabia Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 74. UAE Follicular Lymphoma Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 75. Years Considered
Figure 76. Research Process
Figure 77. Key Executives Interviewed
